title: Eptifibatide does not suppress the increase of inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
abstract: BACKGROUND
  Platelets are involved in inflammatory reactions which play an important role in the development of atherosclerosis and its acute complications. The objective of this study was to test the ability of glycoprotein (GP) IIb-IIIa antagonist eptifibatide to suppress the increase of inflammatory markers in non-ST-segment elevation acute coronary syndrome (ACS).
  
  
  METHODS
  Twenty-five patients with unstable angina and non-ST-segment elevation myocardial infarction received eptifibatide on admission (two 180 microg/kg boluses followed by infusion at 2.0 and 1.3 microg/kg/min for 24 and 48 h, respectively) and 25 were treated without GP IIb-IIIa antagonists. Plasma von Willebrand factor (vWF) and soluble P-selectin were determined at baseline, 48 h and 2 weeks after onset of ACS, and were also measured in a group of healthy volunteers. Serum C-reactive protein (CRP), tumor necrosis factor alpha (TNFalpha), and interleukin 6 (IL6) were measured at baseline, 48 h, 2 weeks and 6 months.
  
  
  RESULTS
  P-selectin was increased at baseline and vWF at baseline, 48 h and 2 weeks in comparison with healthy donors. CRP, TNFalpha, but not IL6 were increased at baseline, 48 h and 2 weeks in comparison with their levels at 6 months. Maximal values of CRP, TNFalpha and vWF were detected at 48 h. At any time point eptifibatide failed to decrease the levels of all tested markers.
  
  
  CONCLUSIONS
  Eptifibatide does not suppress elevated levels of inflammatory markers in patients with non-ST-segment elevation ACS.
authors.affiliation: Russian Cardiology Research and Production Complex, Russian Ministry of Health, 3rd Cherepkovskaya, 15a, 121552 Moscow, Russia.
authors.forename: Alexey A
authors.initials: AA
authors.lastname: Mazaev
authors.forename: Yaroslav A
authors.initials: YA
authors.lastname: Naimushin
authors.forename: Valery P
authors.initials: VP
authors.lastname: Masenko
authors.forename: Mikhail Y
authors.initials: MY
authors.lastname: Ruda
authors.forename: Alexey V
authors.initials: AV
authors.lastname: Mazurov
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000787:Angina Pectoris; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D004562:Electrocardiography; D000077542:Eptifibatide; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000494:pharmacology* / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077542:Eptifibatide